The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans
Recruiting now · Phase 2
Conditions studied: Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez
In brief
There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.
Key facts
- Study ID
- NCT04233749
- Run by
- Henry Ford Health System
- People needed
- 5
- Starts
- 2020-03-17
- Expected to finish
- 2025-12-30
- Last updated by the study team
- 2025-09-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject age 18 and older
- Subject with a diagnosis of LPP, EDP, or AD
- Subject able to understand requirements of the study and risks involved
- Subject able to sign a consent form
- Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment
You may not qualify if…
- Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc)
- Active malignancy, excluding non-melanoma skin cancer
- Moderate to severe renal impairment
- History of migraine with aura
- Current anticoagulant therapy
- Current use of hormonal contraception or hormone replacement therapy in the last 30 days
- A woman who is lactating, pregnant, or planning to become pregnant
Where it is running
- New Center One — Detroit, Michigan, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.